bullish
Concord Biotech IPO - RHP Updates - Continued Growing Although Concentration Risk Remains Elevated
360 Views02 Aug 2023 14:49
Concord Biotech Ltd (658823Z IN) is looking to raise around US$188m in its India IPO. Concord is an India-based biopharma firm, which develops and manufactures fermentation-based APIs.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (6th August 2023) - Concord Biotech, SBFC Fin, Fadu, Mitsui Fudosan, Capitaland Ascott06 Aug 2023
- Concord Biotech IPO - Peer Comparison & Valuation - Smaller in Scale but Wider in Margins04 Aug 2023
- Concord Biotech (Pre-IPO): Niche Offering Amid Lean Competition to Drive Stable Growth02 Aug 2023
- Concord Biotech Pre-IPO - Sales Have Been Growing but Watch Out for Its High Concentration Risk30 Jan 2023
- Concord Biotech Pre-IPO Tearsheet24 Aug 2022
x